More cardiac studies for ultrasound agent:
This article was originally published in Clinica
Executive Summary
Sonus Pharmaceuticals is to begin two further studies of its EchoGen ultrasound contrast agent in the US. The Phase II studies will assess the measurement of left ventricular volume in patients with suspected heart attacks who enter the emergency room with chest pain.